[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebral-ischemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebral-ischemia":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,73,99,124,150,176,202,227,258,280,305],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":53,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100270060","neurologic-stem-cell-treatment-study-100270060",false,"NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[54,55,31,32,56,57,45,58,36,51,48,59],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration","RECRUITING","2026-06-24",{"date":63,"type":64},"2026-06-26","ACTUAL",{"date":66,"type":64},"2016-06",{"date":68,"type":21},"2028-07-31",{"name":70,"class":71},"MD Stem Cells","INDUSTRY",3,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100635891","research-on-the-application-of-sigma-radiopharmaceutical-fbfp-in-cerebral-stroke-100635891","NCT07558577","Research on the Application of Sigma Radiopharmaceutical FBFP in Cerebral Stroke","Inclusion Criteria:\n\n1. Angiography diagnosis shows unilateral anterior circulation head and neck artery stenosis with a diameter reduction of\\>70%, and there is no stenosis in the contralateral anterior circulation or bilateral posterior circulation with a diameter reduction of\\>50%;\n2. Transient ischemic attack or ischemic stroke that must have occurred within the past 12 months in the affected vascular area, with the most recent attack lasting more than 3 weeks;\n3. MRI shows no new intracranial infarction lesions;\n4. No previous infarction lesions in the pontine area;\n5. Either PET\u002FMR blood flow or metabolic imaging shows reduced blood flow and metabolism in the affected hemisphere, with a reduction rate exceeding 10% compared to the contralateral region;\n6. Subjects and informants can complete relevant examinations and follow-up work;\n7. The subject or their authorized representative signs the informed consent form.\n\nExclusion Criteria:\n\n1. Poor image quality due to head movement and other reasons during the scanning process.\n2. There are other neurological disorders that can cause brain dysfunction, such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.\n3. There are other systemic diseases that can cause cognitive impairment, such as liver dysfunction, kidney dysfunction, thyroid dysfunction, severe anemia, folate and vitamin B12 deficiency, special infections (such as syphilis, HIV), alcohol and drug abuse, etc.\n4. Existence of mental and neurological developmental delay.\n5. There are other known diseases that may cause cognitive impairment.\n6. Individuals with severe visual and hearing impairments, claustrophobia, and other conditions who cannot cooperate with MRI examinations.\n7. Suffering from diseases that prevent cooperation in completing cognitive examinations.\n8. Refusal to sign informed consent form during baseline period -",true,"99 Years",{"count":82,"type":21},50,[24],"This clinical research, aims to investigate the uptake of \\[18F\\]FBFP, a Sigma-1 receptor (Sig 1R) PET imaging agent, in stroke participants, compare differences with healthy controls, and evaluate its diagnostic efficacy, providing objective basis for clinical diagnosis and treatment.\n\nThe study will recruit 30 stroke participants (with specific inclusion criteria for unilateral ICA stenosis cases) and 20 gender- and age-matched healthy controls from January 2025 to December 2026. Exclusion criteria cover various neurological and systemic diseases that may affect results, as well as conditions preventing cooperation with examinations.\n\nNo intervention measures are involved. Follow-ups will be conducted at 6 and 12 months to collect clinical data and observe neurological symptom progression. Key measurements include clinical information (via questionnaires and scales like NIHSS and mRS) and PET\u002FMR imaging data (analyzed using PMOD software to calculate SUVmean and uptake differences with cerebellar cortex as reference).\n\nStatistical analysis will use SPSS 21.0, applying descriptive statistics, t-test, ANOVA, regression models, ROC curves, etc., with P \\\u003C 0.05 as significant. Safety evaluation notes PET\u002FMR radiation dose (3-5mSv) is much lower than the safe threshold.\n\nParticipant protection includes ethical approval, informed consent, voluntary participation, risk disclosure, no fees for related exams, and privacy protection. The research team and institution have sufficient resources and qualifications, with outputs including a clinical research cohort and a high-quality paper.",[36,86],"PET \u002F MR","NOT_YET_RECRUITING","2026-04-26",{"date":90,"type":64},"2026-04-30",{"date":92,"type":21},"2026-06-01",{"date":94,"type":21},"2026-12-31",{"name":96,"class":97},"Xuanwu Hospital, Beijing","OTHER",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":98},"100617884","comparison-of-ultrasound-cerebral-perfusion-imaging-with-routine-perfusion-ct-100617884","NCT07324421","Comparison of Ultrasound Cerebral Perfusion Imaging With Routine Perfusion CT","Prospective Monocentric Study Comparing Cerebral Perfusion Parameters From an ULtrasonic Imaging System With Measures Provided by Clinical Routine Perfusion CT","SCULPT","Inclusion Criteria:\n\n* Patient ≥ 18 years old\n* Patient Informed Consent, or from his\u002Fher relative if the patient is not conscious and able to consent\n* Admission to ICU or CCU with indication to perform at least one CTP\n* Affiliated with or benefiting from a social security scheme\n* The subject's current clinical status, as assessed by medical history, physical examination, and\u002For relevant tests, indicates that they do not require immediate medical treatment or emergency care at the time of enrolment.\n\nExclusion Criteria:\n\n* Guardianship, curatorship or any deprivation of liberty by judicial or administrative decision\n* Pregnant or breast-feeding women\n* Known contra-indication or hypersensitivity to SonoVue® (to sulfur hexafluoride microbubbles or to one of its excipients such as polyethylene glycol (PEG))\n* Right-to-left shunts\n* Patients who have undergone craniectomy in the temporal region\n* Patients with open wounds or recent scars in the temporal region\n* Unstable hemodynamic or respiratory state contraindicating transportation to CTP scanner",{"count":82,"type":21},[24],"The primary goal of neurocritical care is to prevent secondary brain injury, which worsens neurological outcomes. Because clinical monitoring is often insufficient due to the patient's condition and medical treatments, multimodal monitoring using biophysical, electrophysiological, and imaging data is essential. In patients with subarachnoid hemorrhage (SAH), the most frequent and severe complication is delayed cerebral ischemia, often linked to arterial vasospasm and potentially leading to infarction. Early diagnosis combines transcranial Doppler (TCD), sensitive to vasospasm, with perfusion CT (CTP), which measures cerebral perfusion; this approach guides therapy and improves prognosis. Ultrasound, especially when enhanced with contrast agents (CEUS), allows non-invasive, bedside, repeated visualization of cerebral blood flow and perfusion-even through the skull. Agents like SonoVue® help quantify perfusion using time-intensity curves. The study aims to assess whether cerebral perfusion measurements from the SYLVER device are equivalent to those from CTP in ICU or CCU patients.",[111,112,113,36,114],"Neuro ICU","Sub Arachnoid Hemorrhage","Neurological Complication","Brain Injuries, Vascular","2025-12-23",{"date":117,"type":64},"2026-01-07",{"date":119,"type":64},"2025-10-25",{"date":121,"type":21},"2026-08-15",{"name":123,"class":71},"Resolve Stroke",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":98},"100610695","study-of-the-rate-of-progression-of-cerebral-ischemia-in-afro-caribbeans-100610695","NCT07230925","Study of the Rate of Progression of Cerebral Ischemia in Afro-Caribbeans","VESPERALS","* inclusion criteria:\n\n  * Patients aged 18 and over, admitted for IC due to LVO verified by medical imaging and hospitalized in neurology.\n  * Patients residing in Guadeloupe\n  * Afro-Caribbean patients: of African ancestry.\n  * Emergency inclusion, with exemption from obtaining consent due to the immediate life-threatening emergency situation of the patient (Article L1122-1-3 of the French Public Health Code); as soon as possible, consent to continue will be sought from the patient or, if applicable, from a relative or a trusted person.\n  * Patients affiliated to a social security scheme or equivalent\n* exclusion criteria:\n\n  * Patients under 18 years old\n  * Non-resident patients in Guadeloupe\n  * Protected persons (articles L1121-5, L1121-6 and L121-8 of the Public Health Code): pregnant or breastfeeding women, persons deprived of their liberty, under guardianship or curatorship)\n  * Withdrawal of consent during the study\n  * Patients not affiliated to a social security or equivalent scheme",{"count":132,"type":21},135,"OBSERVATIONAL","To compare the progression of cerebral ischemia from HF in Afro-Caribbean patients admitted to the CHUG to that of patients from Nantes included in the national ETIS registry.",[136,36,137],"Ischemic Stroke","Endovascular Treatments",[139,140],"Cerebrovascular accident","Cerebral Blood Flow","2025-11-14",{"date":143,"type":64},"2025-11-17",{"date":145,"type":21},"2026-01",{"date":147,"type":21},"2028-01",{"name":149,"class":97},"Centre Hospitalier Universitaire de la Guadeloupe",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":159,"studyType":133,"phases":4,"briefSummary":160,"conditions":161,"keywords":165,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":98},"100310212","stroke-recovery-initiative---registry-for-stroke-research-studies-100310212","NCT03318432","Stroke Recovery Initiative - Registry for Stroke Research Studies","Stroke Recovery Initiative - Stroke Registry","* 18 years of age or older\n* Have suffered a stroke\n* Have ongoing symptoms as a result of the stroke",{"count":158,"type":21},60000,"5 Years","The Stroke Recovery Initiative is a nation-wide participant recruitment registry that connects people who have had a stroke with researchers who are working to develop new approaches to improve recovery after stroke.",[31,162,136,163,164,36,35,37,55],"Acute Stroke","Hemorrhagic Stroke","Subarachnoid Hemorrhage",[31,162,136,163,36,35,37,55,166],"Stroke Recovery","2025-09-26",{"date":169,"type":64},"2025-10-02",{"date":171,"type":64},"2013-02-09",{"date":173,"type":21},"2028-09",{"name":175,"class":97},"University of California, San Francisco",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100595325","perfusion-imaging-score-to-predict-delayed-cerebral-ischemia-100595325","NCT07030985","Perfusion Imaging Score to Predict Delayed Cerebral Ischemia","Inclusion Criteria:\n\n* Age \\>18 years with a diagnosis of aSAH\n\nExclusion Criteria:\n\n* chronic kidney disease stage IV\n* pregnancy\n* allergy to iodine that precludes CTP\n* subjects with significant aphasia, blindness, or other factors that limit their participation in the cognitive assessment",{"count":183,"type":21},55,[24],"Aneurysmal subarachnoid hemorrhage (aSAH) is a significant public health concern, annually affecting over 30,000 Americans and ranking among the leading causes of stroke-related life-years lost in individuals aged 65 and younger. Delayed cerebral ischemia (DCI), occurring in 20% to 40% of aSAH survivors, is a major contributor to brain injury and disability. Timely recognition of DCI is crucial for improving neurological outcomes and preventing irreversible cerebral infarction. However, current methods have substantial limitations, hindering early and reliable detection. This proposal seeks to address these challenges through determining the ability of perfusion imaging to predict DCI and correlate with neurological and neuropsychological outcomes.",[187,36],"Aneurysmal Subarachnoid Hemorrhage",[189,190,191,192],"computed tomography perfusion","brain perfusion","early detection","prediction","2025-06-23",{"date":195,"type":64},"2025-06-26",{"date":197,"type":21},"2025-09",{"date":199,"type":21},"2026-09",{"name":201,"class":97},"Stanford University",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":98},"100439135","autologous-mitochondrial-transplant-for-cerebral-ischemia-100439135","NCT04998357","Autologous Mitochondrial Transplant for Cerebral Ischemia","Study Title: Autologous Mitochondrial Transplant for Cerebral Ischemia","Inclusion Criteria:\n\n* Eligible for endovascular thrombectomy to treat acute large vessel occlusion\n* Eligible for angioplasty (microcatheter-based balloon\u002Fmechanical and chemical angioplasty) to treat acute cerebral vasospasm after aneurysmal subarachnoid hemorrhage\n* Subjects for whom there is likely to be enough time to obtain meaningful consent from patient or legally-authorized representative\n\nExclusion Criteria:\n\n* Unable to receive a brain MRI scan\n* Known mitochondrial disease\n* Hemodynamically unstable patients in whom standard of care endovascular reperfusion treatment cannot safely be performed or completed","85 Years",{"count":211,"type":21},20,[24],"The investigators propose to infuse healthy autologous mitochondria into cerebral vessels supplying brain tissue experiencing ischemia in patients who undergo standard-of- care endovascular reperfusion therapy.",[36],[216,217],"autologous mitochondrial transplantation","ischemic stroke","2025-05-15",{"date":220,"type":64},"2025-05-21",{"date":222,"type":64},"2021-04-29",{"date":224,"type":21},"2026-10-29",{"name":226,"class":97},"University of Washington",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":239,"conditions":240,"keywords":245,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":257},"100415967","phase-2-effect-of-xenon-on-brain-injury-after-aneurysmal-subarachnoid-hemorrhage-100415967","NCT04696523","Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage","Effect of Xenon on Brain Injury, Neurological Outcome and Survival in Patients After Aneurysmal Subarachnoid Hemorrhage","Xe-SAH","Inclusion Criteria:\n\nTo be considered eligible to participate in this study, a SAH subject must meet the inclusion criteria listed below:\n\n1. Informed consent obtained from the next of kin or legal representative\n2. Aneurysmal subarachnoid hemorrhage visible on CTA or DSA.\n3. Deterioration of consciousness to Hunt-Hess 3-5\n4. Age of ≥ 18 years\n5. Intubated.\n6. GCS 3-12 obtained off neuromuscular blocking agents\n7. Xenon treatment can be started within 6 hours after onset of SAH symptoms\n\nExclusion Criteria:\n\nAn aSAH subject may not be enrolled in the trial if he\u002Fshe meets any one of the exclusion criteria below:\n\n1. Acute or chronic traumatic brain injury\n2. Maximum diameter of intracerebral hemorrhage \\> 2.5 cm\n3. Pneumothorax or pneumomediastinum,\n4. Acute lung injury requiring ≥ 60% FIO2 (fraction of inspired oxygen).\n5. Systolic arterial pressure \\\u003C 80 mmHg or mean arterial pressure \\\u003C 60 mmHg for over 30 min period\n6. Bilaterally fixed and dilated pupils\n7. Positive pregnancy test, known pregnancy, or current breast-feeding\n8. Neurological deficiency due to traumatic brain injury or other neurological illness\n9. Imminent death or current life-threatening disease\n10. Current enrollment in another interventional study\n11. The subject is known to have clinically significant laboratory abnormality, medical condition (such as decompensated liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the subject to participate in this clinical trial.\n12. Presence of implants or foreign bodies which are not known to be MRI safe",{"count":236,"type":21},160,[238],"PHASE2","An investigator-initiated clinical drug study\n\nMain Objective:\n\nTo explore neuroprotective properties of xenon in patients after aneurysmal subarachnoid hemorrhage (SAH).\n\nPrimary endpoint: Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly higher in the xenon group than in the control group as assessed with the 1st magnetic resonance imaging (MRI).\n\nAfter confirmation of aSAH and obtaining a signed assent subjects will be randomized to the following groups:\n\nControl group: Standard of Care (SOC) group: Air\u002Foxygen and Normothermia 36.5-37.5°C; Xenon group: Normothermia 36.5-37.5°C +Xenon inhalation in air\u002Foxygen for 24 hours. Brain magnetic resonance imaging techniques will be undertaken to evaluate the effects of the intervention on white and grey matter damage and neuronal loss. Neurological outcome will be evaluated at 3, 12 and 24 months after onset of aSAH symptoms Investigational drug\u002Ftreatment, dose and mode of administration: 50±2 % end tidal concentration of inhaled xenon in oxygen\u002Fair.\n\nComparative drug(s)\u002Fplacebo\u002Ftreatment, dose and mode of administration: Standard of care treatment according to local and international consensus reports.\n\nDuration of treatment: 24 hours\n\nAssessments:\n\nBaseline data Information that characterizes the participant's condition prior to initiation of experimental treatment is obtained as soon as is clinically reasonable. These include participant demographics, medical history, vital signs, oxygen saturation, and concentration of oxygen administered.\n\nAcute data The collected information will contain quantitative and qualitative data of aSAH patients, as recommended by recent recommendations of the working group on subject characteristics, and including all relevant Common Data Elements (CDE) can be applied. Specific definitions, measurements tools, and references regarding each SAH CDE can be found on the weblink here: https:\u002F\u002Fwww.commondataelements.ninds.nih.gov\u002FSAH.aspx#tab=Data\\_Standards.",[241,242,36,35,243,244],"Subarachnoid Hemorrhage, Aneurysmal","Cerebral Injury","Cardiac Event","Cardiac Failure",[246],"xenon, neuroprotection, aneurysmal subarachnoid hemorrhage","2025-04-28",{"date":249,"type":64},"2025-05-01",{"date":251,"type":64},"2025-04-22",{"date":253,"type":21},"2029-12-31",{"name":255,"class":256},"Turku University Hospital","OTHER_GOV",7,{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":98},"100564433","study-on-the-role-of-human-serum-albumin-in-large-acute-ischemic-stroke-of-anterior-circulation-after-thrombectomy-100564433","NCT06629116","Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy","Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy: A Prospective, Multicenter, Open-label, Endpoint-blinded, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years old.\n2. Acute ischemic stroke patients with NIHSS score ≥ 6.\n3. Pre-stroke mRS (modified Rankin Scale) score ≤ 1.\n4. Onset of symptoms to presentation within 24 hours, including wake-up strokes or strokes without witnessed onset; the time of symptom onset is defined as the \"last seen normal\" time.\n5. Confirmed by CTA\u002FMRA\u002FDSA to have anterior circulation large vessel occlusive ischemic stroke (occlusion of the internal carotid artery or M1 or M2 segments of the middle cerebral artery), responsible for acute ischemic stroke signs and symptoms.\n6. ASPECTS (Alberta Stroke Program Early CT Score) on NCCT (non-contrast CT) 3-6 or cerebral perfusion imaging: core infarct volume (rCBF ≤ 30%) 50-100 ml.\n7. Achieving vessel reperfusion of mTICI (modified Thrombolysis in Cerebral Infarction) grade 2b or 3 through mechanical thrombectomy.\n8. Written informed consent signed by the patient or their legally authorized representative.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by head CT or MRI.\n2. Pre-stroke mRS score \\> 2.\n3. Severe allergy or absolute contraindication to iodine-based contrast agents.\n4. Systolic blood pressure \\> 185 mmHg or diastolic blood pressure \\> 110 mmHg, and inability to control with antihypertensive medication.\n5. Blood glucose \\\u003C 50 mg\u002Fdl (2.8 mmol\u002FL) or \\> 400 mg\u002Fdl (22.2 mmol\u002FL) and difficult to correct.\n6. Genetic or acquired bleeding diathesis, deficiency of coagulation factors, or oral anticoagulation with INR \\> 1.7.\n7. Severe renal dysfunction defined as serum creatinine \\> 3.0 mg\u002Fdl (or 265.2 μmol\u002Fl) or glomerular filtration rate (GFR) \\\u003C 30 ml\u002Fmin, or need for hemodialysis or peritoneal dialysis.\n8. Expected life expectancy \\\u003C 6 months.\n9. Anticipated inability of the patient to complete the 90-day follow-up.\n10. Suspected aortic dissection.\n11. Brain tumors, intracranial aneurysms, or arteriovenous malformations with mass effect on imaging.\n12. Neurological or psychiatric disorders affecting the assessment of the disease before the patient's stroke.\n13. Pregnancy or reproductive-age women with positive urinary or serum β-human chorionic gonadotropin (HCG) test.\n14. Currently participating in other clinical trials that may interfere with the results of this trial.\n15. History of allergy to albumin.\n16. Need for intermittent or long-term concomitant acute or chronic pulmonary diseases.\n17. Congestive heart failure for any reason in the past 6 months or any condition requiring medication, hospitalization, etc., related to heart failure.\n18. Symptomatic or diagnosed acute myocardial infarction, or occurrence of acute myocardial infarction within the past 6 months.\n19. Other situations that the investigator believes are not suitable for participation or may pose significant risks to the patient.","80 Years",{"count":267,"type":21},100,[24],"This project intends to explore the therapeutic efficacy of human serum albumin in mitigating postoperative cerebral edema and enhancing clinical outcomes following mechanical thrombectomy in patients with acute anterior circulation large-core ischemic stroke.",[36],"2024-10-04",{"date":273,"type":64},"2024-10-08",{"date":275,"type":64},"2024-01-30",{"date":277,"type":21},"2027-05-30",{"name":279,"class":97},"Tingyu-Yi",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":22,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":98},"100529795","remote-ischemic-conditioning-for-cerebral-ischemia-in-patients-with-takayasu-arteritis-taric-1-100529795","NCT06178419","Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)","Safety and Efficacy of Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis: a Prospective Cohort Study","TARIC-1","Inclusion Criteria:\n\n* All patients fulfilled the 1990 American College of Rheumatology Classification Criteria for TAK\n* Inactive state\n* Male and female, aged 18-65 years old\n* The presence of supra-aortic vascular involvement ( including but not limited to the left and right sides of the common carotid artery, subclavian artery, vertebral artery involvement )\n* Decreased cerebral blood perfusion in the whole brain ( compared with healthy people ) or local ( left and right brain contrast ) suggested by pseudo-Continuous arterial spin labeling ( pCASL ) -MRI\n* Voluntary participation in this study, signed informed consent\n\nExclusion Criteria:\n\n* Complications that endanger the function of important organs, such as uncontrollable heart failure, severe heart valve disease, severe hypertension, severe myocardial ischemia, pulmonary hypertension, acute cerebral infarction, arterial dissection or aneurysm rupture, etc\n* There are serious complications, such as poorly controlled diabetes, renal insufficiency, cardiopulmonary insufficiency, mental illness or malignant tumor\n* There were moderate to severe stenosis of brachial artery in both upper limbs","65 Years",{"count":290,"type":21},44,[24],"The aim of this study is to evaluate the safety and efficacy of remote ischemic conditioning ( RIC ) in the protection of cerebral ischemia in patients with Takayasu arteritis ( TAK ). The study was designed as a prospective, double-blind, exploratory randomized controlled study. The entire study included a screening period and a treatment observation period ( a total of 24 weeks ). All patients with cerebral ischemia of TAK will be randomly divided into RIC group and sham RIC group at 1:1 ratio. On the basis of receiving the conventional drug therapy, the patients will be treated with RIC or sham RIC treatment twice daily for six month. The clinical data of patients at baseline and each follow-up will be collected, including basic information, disease activity assessment, laboratory indicators, imaging indicators, treatment data, adverse events, etc.The Primary outcome is the mean cerebral blood flow improvement rate ( mCBF-IR ) of TAK patients after 24 weeks-treatment. Secondary endpoints include the incidence of major adverse cerebrovascular events ( MACE ) , the change value of arterial transit time ( ATT ) in pCASL hypoperfusion area compared with baseline, occurrence of RIC-related adverse reactions, the changes of hematological indexes and disease activity score, etc. This study will provide insights into the preliminary proof of principle, safety, and efficacy of RIC in cerebral ischemia in patients with Takayasu arteritis ( TAK ), and this data will provide parameters for future larger scale clinical trials if efficacious.",[36,294],"Takayasu Arteritis",[36,294,296],"remote ischemic conditioning","2024-09-12",{"date":299,"type":64},"2024-09-19",{"date":301,"type":64},"2024-01-01",{"date":303,"type":21},"2025-07-31",{"name":96,"class":97},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":98},"100332383","a-new-parameter-derived-from-dsa-to-evaluate-cerebral-perfusion-100332383","NCT03607565","A New Parameter Derived From DSA to Evaluate Cerebral Perfusion","The Association Between a New Parameter Derived From DSA and Outcomes in Cerebral Ischemia","Inclusion Criteria:\n\n1. Cerebral ischemia\n2. patients undergone DSA\n\nExclusion Criteria:\n\n1.cerebral hemorrhage",{"count":313,"type":21},30000,"This observational study focus on a new parameter of cerebral perfusion derived form digital substraction angiography.",[36],"2023-08-31",{"date":318,"type":64},"2023-09-01",{"date":320,"type":64},"2018-07-15",{"date":322,"type":21},"2038-07-15",{"name":324,"class":256},"Xi'an No.3 Hospital"]